
8-K
1
tm2012857d1_8k.htm
FORM 8-K



     





 

 



United
States

SECURITIES
AND EXCHANGE COMMISSION 

Washington,
D.C. 20549 

    

Form 8-K

  

Current Report 

Pursuant to Section 13 or 15(d) of the


Securities Exchange Act of 1934 

 

March 10, 2020

Date of Report (Date of earliest event reported)

 

LifeSci
Acquisition Corp.

(Exact Name of Registrant as Specified in
its Charter)

 



    Delaware
     
    001-39244
     
    83-3197402

    
        (State or other jurisdiction of incorporation) 
     
    
        (Commission File Number) 
     
    
        (I.R.S. Employer Identification No.)

 



    
        250 W. 55th St., #3401
        New York, NY
     
    10019

    
        (Address of Principal Executive
Offices) 
     
    
        (Zip Code) 

 

Registrant’s telephone number, including
area code: (646) 889-1200 

 

N/A

 



(Former name or former address, if changed
since last report) 




 

Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 


¨Written communications pursuant to Rule 425 under the
Securities Act


 


¨Soliciting material pursuant to Rule 14a-12 under the
Exchange Act


 


¨Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act


 


¨Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act


 

Securities registered pursuant to Section 12(b) of the Act:

 



    
Title of each class
     
    
Trading Symbol(s)
     
    Name of each exchange on which registered

    Common Stock
     
    LSAC
     
    The Nasdaq Stock Market LLC

    Warrants
     
    LSACW
     
    The Nasdaq Stock Market LLC

    Units
     
    LSACU
     
    The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

 




     
     
    

 

Item 8.01. Other Events

 

As previously
disclosed on a Current Report on Form 8-K dated March 5, 2020, on March 10, 2020 LifeSci Acquisition Corp. (the “Company”)
consummated its initial public offering (“IPO”) of 6,000,000 units (the “Units”). Each Unit consists
of one share of common stock, par value $0.0001 per share (“Common Stock”) and one warrant (“Warrant”)
entitling its holder to purchase one-half of one share of Common Stock at a price of $11.50 per whole share. The Units were sold
at an offering price of $10.00 per Unit, generating gross proceeds of $60,000,000.

 

As of March 10, 2020, a total of $60,000,000
of the net proceeds from the IPO and the private placement consummated simultaneously with the closing of the IPO were deposited
in a trust account established for the benefit of the Company’s public stockholders.

 

An audited balance sheet as of March 10,
2020 reflecting receipt of the proceeds upon consummation of the IPO and the private placement is included with this report as
Exhibit 99.1

 

Item 9.01. Financial Statements and Exhibits.

 



    
        Exhibit No.
    
        Description

     
     

    99.1
    Balance Sheet dated March 10, 2020

     
     

 



     
     
    


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 16, 2020

 

LIFESCI ACQUISITION CORP.



 

By: 	/s/ Andrew McDonald                                                                  	
Name: Andrew McDonald
Title: Chief Executive Officer

 




     
    

 

 








